The Charles T. Campbell Eye Microbiology Lab
UPMCUniversity of Pittsburgh Schools of the Health Sciences
HomeContact InformationLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchPhotos

Ocular Microbiology and Immunology Group
Back to OMIG Main Page

< Previous | 2019 Agenda and Abstracts | Next >


2019 OMIG Abstract

Efficacy of Dilute Topical Ophthalmic Povidone-Iodine against Multi- Drug Resistant Bacterial Biofilms, Fungal Biofilms and Fungal Spores

Jesse Pelletier, MD1,2, Samuel Barone, MD2, Kara Capriotti, MD2,3, Joseph Capriotti, MD2
1Plessen Ophthalmology, Christiansted, USVI; 2Veloce BioPharma, LLC, Fort Lauderdale, FL; 3Bryn Mawr Skin and Cancer Institute, Rosemont, PA

Purpose: The role of biofilms in ocular infection has begun to be realized. A novel topical ophthalmic formulation of dilute povidone-iodine (PVP-I) was evaluated against multi-drug resistant biofilm forming pathogens.

Methods: The in vitro Minimum Biofilm Eradication Concentration (MBEC) of the PVP-I formulations was determined against established biofilms of multi-drug resistant Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans, as was the Minimal Inhibitory Concentration (MIC) of the same formulations against Candida auris, Trichophton mentagrophytes, Microsporum canis, Candida albicans and Aspergillus fumigatus. The multi-drug resistant biofilms were developed on solid surfaces using the Calgary Biofilm Device plate. MBEC concentration was determined for test drug and for control samples of known antimicrobials: ciprofloxacin and itraconazole. Quality control fungal strains were grown on Sabouraud’s Dextrose Agar plates for the anti-fungal susceptibility. MIC was determined for each test drug and for control samples of know antifungals, fluconazole and amphotericin B.

Results: The PVP-I formulations completely eliminated all biofilms of bacterial and fungal species in the test systems. Biofilm eradication assay showed the ability of PVP-I formulations to disrupt a pre-existing robust biofilm of the microorganisms. PVP-I solutions at concentration as low as 0.25% (w/w) and PVP-I gel at 0.25% (w/w) completely eradicated the biofilms of all the test microorganisms. Comparator antibiotics were ineffective in eradicating biofilms of test microorganism except ciprofloxacin which had a MBEC value of 0.25 µg/mL against one bacterial biofilm, S. aureus ATCC 33591. MIC assay showed the anti-fungal activity of low-dose PVP-I formulations. At serially diluted concentrations as low as 6.25% and 3.125%, 1% PVP-I solutions showed anti-fungal activity against all the test strains. Fluconazole was ineffective against C. albicans, A. fumigatus and C. auris. Amphotericin B had good anti-fungal activity against all the strains tested.

Conclusion: Dilute, topical PVP-I disrupted established, antibiotic-resistant biofilms. Further exploration in vitro and in vivo is warranted.

Disclosure: C, O, P (JP, Veloce BioPharma); E, O (SB, Veloce BioPharma); E, L, O (JC, Veloce BioPharma)


<Previous | 2019 Agenda and Abstracts | Next >